Overview:
Biomarker-driven advancements, including immune checkpoint inhibitors and antibody-drug conjugates targeting HER2 and TROP2, have provided critical options for patients with endometrial cancer. However, disparities in access have meant these advancements do not reach all patients who might benefit from them.
In this virtual Live Tumor Board CE-certified Spotlight
symposium, case-based discussions will explore topics of epidemiology,
inequalities, and current and emerging immunotherapy options for patients with
endometrial cancer. Expert faculty will provide invaluable clinical pearls and
practical strategies to help learners apply trial data to the clinical setting.
In the final module, faculty will provide detailed answers to audience
questions that could not be addressed during the presentation at the 17th Annual International Symposium on Gynecologic
Malignancies.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Describe the evidence for contemporary and emerging biomarker testing strategies in individualizing therapy for patients with endometrial cancer
- Evaluate recent clinical trial data for the use of biomarker-driven therapies in advanced and recurrent endometrial cancer
- Apply shared decision-making strategies to develop personalized treatment plans that reflect molecular findings, patient goals, and access consideration
Target Audience:
This
educational activity is directed toward oncologists, gynecologists, nurses,
NPs/PAs, and other HCPs involved in the diagnosis and treatment of endometrial
cancer.